Keyphrases
Neuroblastoma
73%
Children's Oncology Group
51%
Liberia
34%
Ebola Virus Disease
33%
High-risk Neuroblastoma
32%
Clinical Features
25%
Refractory Neuroblastoma
25%
Tumor Biology
25%
Overall Survival
22%
Survivors
19%
Tumor
19%
MYCN Amplification
18%
Event-free Survival
18%
Tumor Outcome
16%
Local Control
13%
Extent of Resection
13%
Ebola
13%
Local Progression
13%
Blood Donors
13%
123I-MIBG
12%
Cumulative Incidence
12%
Protein Expression
11%
Infectious Diseases
11%
Resection
11%
Ebola Virus
10%
Malawi
10%
Response Evaluation Criteria in Solid Tumors (RECIST)
9%
Phase II Study
9%
Safe Blood
9%
Dinutuximab
9%
Phase II Trial
9%
Disease Progression
9%
Putative Drug Targets
9%
Granulocyte Colony-stimulating Factor (G-CSF)
9%
Antitumor Activity
9%
Longitudinal Cohort Study
9%
West Africa
9%
ATRX mutation
8%
Historical Period
8%
Modern History
8%
Paucisymptomatic
8%
Early Phase Clinical Trials
8%
Isotretinoin
8%
Site Response
8%
Hu14.18-IL2
8%
Progression-free Survival
8%
Observational Cohort Study
8%
VMAT1
8%
Clinical Correlation
8%
Transfusion-transmitted Infections
8%
Medicine and Dentistry
Ganglioneuroblastoma
100%
Oncology
50%
Ebolavirus
33%
Virus Infection
33%
Neoplasm
31%
Surgery
27%
Overall Survival
25%
Clinical Feature
25%
Tumor Biology
25%
Disease
21%
Event Free Survival
19%
Infection
19%
Prevalence
16%
Blood Donor
16%
Primary Tumor
14%
Protein Expression
11%
(3 Iodobenzyl)guanidine
10%
Dinutuximab
9%
Biological Marker
9%
Sequela
9%
Cohort Analysis
9%
Disease Exacerbation
9%
Cumulative Incidence
8%
Lymph Node Irradiation
8%
Progression Free Survival
8%
Protein Family
8%
Cataract Surgery
8%
Outcome of Cataract
8%
Child Growth
8%
Cohort Study
8%
Communicable Disease
8%
Vesicular Monoamine Transporter 2
8%
Vesicular Monoamine Transporter 1
8%
Radiation Therapy
8%
Vesicular Monoamine Transporter
8%
Somatostatin Receptor 2
8%
Temsirolimus
8%
Intraocular Pressure
8%
Neuropeptide Y
8%
Malignant Neoplasm
6%
Karyorrhexis
5%
Recurrent Disease
5%
Response Evaluation Criteria in Solid Tumors
5%
Patient with Neuroblastoma
5%
Receptor
5%